Alvotech (NasdaqGM:ALVO): Is the Market Overlooking Its True Value?

Alvotech (NasdaqGM:ALVO) has seen its stock price move only slightly in recent days, rising just over 1% for the week and gaining 3% over the past month. However, performance in the past 3 months is down about 11% as investors sort through recent developments for direction.

See our latest analysis for Alvotech.

Stepping back, Alvotech’s 1-year total shareholder return has landed in negative territory, which suggests momentum has been fading despite a few recent bumps upward in its share price. While short-term moves can reflect shifting sentiment around growth or risk, the longer view shows investors are still weighing the company’s long-term promise against ongoing uncertainties.

If you’re curious about where else the action is, consider expanding your search and discover fast growing stocks with high insider ownership.

With shares trading at less than half of analyst price targets and solid revenue growth underway, are investors overlooking a bargain? Or has the market already accounted for Alvotech’s prospects for future expansion?

Most Popular Narrative: 53.1% Undervalued

The current share price of $8.20 is far below what the most popular narrative estimates as a fair value for Alvotech, creating a wide gap between the market and this narrative’s outlook. Investors are watching for the company's next major catalysts to see if this disconnect will close.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent. This could potentially drive a significant change in topline revenue once approvals are secured.

Read the complete narrative.

Curious how this bullish narrative gets to such a high fair value? The secret sauce is bold revenue and margin expansion assumptions—numbers rarely seen in pharma. Which combinations of growth, profits, and valuation multiples unlock this price target? Do not miss the answer. See what drives these projections for yourself.

Result: Fair Value of $17.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, delays in regulatory approvals or intensifying price competition could quickly challenge these bullish assumptions and test Alvotech’s ability to deliver on growth promises.

Find out about the key risks to this Alvotech narrative.

Build Your Own Alvotech Narrative

Want to uncover a different story or dig deeper with your own analysis? You can assemble your own Alvotech outlook in just a few minutes. Do it your way.

A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Smart Investment Ideas?

Why stop at one stock? Broaden your investment horizons and spot the next opportunity before the crowd does by using Simply Wall Street’s powerful screeners.

• Tap into steady income by checking out these 19 dividend stocks with yields > 3% with yields above 3%, which may be suitable for investors seeking reliable returns.
• Discover opportunities in Artificial Intelligence by scanning these 24 AI penny stocks, highlighting stocks positioned for growth and innovation breakthroughs.
• Explore value with these 910 undervalued stocks based on cash flows, where you can find stocks trading below their estimated worth based on cash flow fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com